Fucoidan and Lung Function: Value in Viral Infection.

Area of Science:

• Pulmonology
• Immunology
• Virology

Background:

• Viral infections, including SARS-CoV-2, cause acute and chronic lung damage by suppressing innate immunity and increasing inflammation.
• Compromised lung function is a common outcome of both infectious and non-infectious diseases.

Purpose of the Study:

• To review current research on fucoidan's effects on viral lung infections and associated damage.
• To explore fucoidan's potential as a therapeutic agent against SARS-CoV-2-induced lung injury.

Main Methods:

• Review of existing clinical and animal studies on fucoidan.
• Analysis of research on fucoidan's impact on innate immunity and inflammation.
• Examination of studies investigating fucoidan's role in viral infection models.

Main Results:

• Fucoidans have demonstrated the ability to enhance innate immunity and reduce inflammation in clinical and animal studies.
• Dietary fucoidan has shown efficacy in mitigating pulmonary damage during acute viral infections.
• While some studies show direct inhibition of SARS-CoV-2 in vitro, this effect is not universally observed.

Conclusions:

• Fucoidans show promise in managing lung damage caused by viral infections, particularly SARS-CoV-2.
• Targeting innate immunity and inflammation with fucoidan may offer a strategy to combat viral lung pathologies.
• Further research is warranted to fully elucidate fucoidan's therapeutic potential for viral lung infections.